AT-IAP is a potent, orally bioavailable, dual XIAP/cIAP1 inhibitor with EC50 of 5.1/0.32 nM, respectively.
AT-IAP exhibits MDA-MB-231 cell proliferation inhibition with IC50 of 4.4 nM.
AT-IAP decreases basal and TNF-α-induced cIAP-1 expression in CaP cells, switches TNF-α signaling from pro-survival to pro-apoptotic and increases radiation sensitivity of CaP cells in co-culture with THP-1 cells.
AT-IAP shows in vivo efficacy in Balb/c scid mice bearing MDA-MB-231 xenografts.
